![](/img/cover-not-exists.png)
Patients With Acute Myeloid Leukemia and RAS Mutations Benefit Most From Postremission High-Dose Cytarabine: A Cancer and Leukemia Group B Study
Neubauer, A., Maharry, K., Mrozek, K., Thiede, C., Marcucci, G., Paschka, P., Mayer, R. J., Larson, R. A., Liu, E. T., Bloomfield, C. D.Volume:
26
Language:
english
Journal:
Journal of Clinical Oncology
DOI:
10.1200/JCO.2007.14.0418
Date:
October, 2008
File:
PDF, 175 KB
english, 2008